Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: A systematic review and meta-analysis

International Journal of Colorectal Disease

Volumn 28, Issue 8, 2013, Pages 1039-1047

  Lu, Yu Yu ^a   Chen, Jin Hua ^b   Chien, Chun Ru ^c,d   Chen, William Tzu Liang ^c,d   Tsai, Shih Chuan ^a   Lin, Wan Yu ^a,d   Kao, Chia Hung ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Carcinoembryonic antigen; FDG PET; Meta analysis; PET CT; Systematic review

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WHOLE BODY PET;

EID: 84883556878     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-013-1659-z     Document Type: Review

References (36)

1. Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
2. Goldberg RM (2006) Intensive surveillance after stage II or III colorectal cancer: is it worth it? J Clin Oncol 24:330-331 (Pubitemid 46630448)
3. Parker SL, Tong T, Bolden S et al (1997) Cancer statistics, 1997. CA Cancer J Clin 47:5-27 (Pubitemid 27050847)
4. Obrand DI, Gordon PH (1997) Incidence and patterns of recurrence following curative resection of colon cancer. Dis Colon Rectum 40:15-24 (Pubitemid 27056393)
5. Vernava AM III, Longo WE, Virgo KS et al (1994) Current follow-up strategies after resection of colon cancer. Results of a survey of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 37:573-583 (Pubitemid 24180779)
6. Carriquiry LA, Pineyro A (1999) Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 42:921-929 (Pubitemid 29328465)
7. Mitchell EP (1998) Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol 25:12-20 (Pubitemid 28478051)
8. Moss AA (1989) Imaging of colorectal carcinoma. Radiology 170:308-310 (Pubitemid 19035641)
9. Tempero M, Brand R, Holdeman K et al (1995) New imaging techniques in colorectal cancer. Semin Oncol 22:448-471
10. Ruhlmann J, Schomburg A, Bender H et al (1997) Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 40:1195-1204 (Pubitemid 27433309)
11. Flanagan FL, Dehdashti F, Ogunbiyi OA et al (1998) Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227:319-323 (Pubitemid 28131010)
12. Flamen P, Stroobants S, Van Cutsem E et al (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d glucose in recurrent colorectal cancer. J Clin Oncol 17:894-901 (Pubitemid 29109320)
13. Zervos EE, Badgwell BD, Burak WE Jr et al (2001) Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 130:636-643 (Pubitemid 32964609)
14. Simo M, Lomena F, Setoain J et al (2002) FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 23:975-982 (Pubitemid 35178298)
15. Liu FY, Chen JS, Changchien CR et al (2005) Utility of 2-fluoro-2-deoxy-d-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum 48:1900-1912 (Pubitemid 41437674)
16. Maldonado A, Sancho F, Cerdan J et al (2000) FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level: experience in 72 patients. Clin Positron Imaging 3:170
17. Kalff V, Hicks RJ, Ware RE et al (2002) The clinical impact of (18)F-FDG-PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43:492-499 (Pubitemid 34286344)
18. Chen LB, Tong JL, Song HZ et al (2007) (18)FDG-PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 13:5025-5029
19. Chen YK, Yeh CL, Tsui CC et al (2011) F-18 FDG-PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 36:553-559
20. Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12:1293-1316 (Pubitemid 23230833)
21. Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31 (Pubitemid 44285240)
22. Imdahl A, Reinhardt MJ, Nitzsche EU et al (2000) Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 385:129-134 (Pubitemid 30202938)
23. Staib L, Schirrmeister H, Reske SN et al (2000) Is (18)F- fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180:1-5
24. Hung GU, Shiau YC, Tsai SC et al (2001) Value of 18F-fluoro-2- deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 21:1375-1378
25. Imbriaco M, Akhurst T, Hilton S et al (2000) Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging 3:107-114
26. Choi MY, Lee KM, Chung JK et al (2005) Correlation between serum CEA level and metabolic volume as determined by FDG-PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 19:123-129 (Pubitemid 40745695)
27. Lee JH, Park SG, Jee KN et al (2010) Performance of FDG-PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun 31:576-582
28. Sarikaya I, Bloomston M, Povoski SP et al (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64-71 (Pubitemid 46995478)
29. Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 37:862-869 (Pubitemid 32323964)
30. Libutti SK, Alexander HR Jr, Choyke P et al (2001) A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 8:779-786 (Pubitemid 34003326)
31. Shen YY, Liang JA, Chen YK et al (2006) Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 53:348-350
32. Kyoto Y, Momose M, Kondo C et al (2010) Ability of 18F-FDG-PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med 24:395-401
33. Metser U, You J, McSweeney S et al (2010) Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG-PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol 194:766-771
34. Mittal BR, Senthil R, Kashyap R et al (2011) 18F-FDG-PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun 32:789-793
35. Ozkan E, Soydal C, Araz M et al (2012) The role of 18F-FDG-PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nucl Med Commun 33:395-402
36. Sanli Y, Kuyumcu S, Ozkan ZG, et al. (2012) The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med 26:551-558